Mediator occupies a key role in protein coding genes expression in mediating the contacts between gene specific factors and the basal transcription machinery but little is known regarding the role of each Mediator subunits. Mutations in MED12 are linked with a broad spectrum of genetic disorders with X-linked intellectual disability that are difficult to range as Lujan, Opitz-Kaveggia or Ohdo syndromes. Here, we investigated several MED12 patients mutations (p.R206Q, p.N898D, p.R961W, p.N1007S, p.R1148H, p.S1165P and p.R1295H) and show that each MED12 mutations cause specific expression patterns of JUN, FOS and EGR1 immediate early genes (IEGs), reflected by the presence or absence of MED12 containing complex at their respective promoters. Moreover, the effect of MED12 mutations has cell-type specificity on IEG expression. As a consequence, the expression of late responsive genes such as the matrix metalloproteinase-3 and the RE1 silencing transcription factor implicated respectively in neural plasticity and the specific expression of neuronal genes is disturbed as documented for MED12/p.R1295H mutation. In such case, JUN and FOS failed to be properly recruited at their AP1-binding site. Our results suggest that the differences between MED12-related phenotypes are essentially the result of distinct IEGs expression patterns, †
Introduction
Mammalian mediator (MED) is an evolutionary conserved multi-protein complex that is a key regulator of gene expression involved in cell growth, homeostasis, development and differentiation (1) (2) (3) . Mediator is composed of more than 30 subunits, arranged in four different modules (Fig. 1A) . Upon gene activation, MED conveys essential information from transcriptional regulatory proteins bound at DNA responsive elements to RNA polymerase II (Pol II) machinery bound at the transcription start site (TSS) (4) (5) (6) .
Dysfunction of the transcriptional machinery components has been shown to elicit a range of effects on cell states (proliferation or differentiation) giving rise to diverse pathologies, including cancers (7) . Mutations in MED subunits are also associated with a wide range of genetic disorders, such as infantile cerebral and cerebellar atrophy (MIM: 613668) (MED17, MIM: 603810) (8), Charcot-Marie Tooth disease (MIM: 605589) (MED25, MIM: 610197) (9) and non-syndromic intellectual disability (MIM: 614249) (MED23, MIM: 605042) (10) and (MED13L, MIM: 608771) (11) ; most of them exhibiting neurological defects (12) . Germ line mutations of MED12 (MIM: 300188) have already been found in several genetic disorders associated with X-linked intellectual disability (XLID) (13) , such as Opitz-Kaveggia syndrome also named FG syndrome (MIM: 305450) (p.R961W) (14) and (p.G958E) (15) , Lujan syndrome (MIM: 309520) (p.N1007S) (16) and Ohdo syndrome (MIM: 249620) (p.S1165P, p.R1148H and H1729N) (17, 18) . More recently, an important number of mutations have also been associated with non-syndromic XLID (p.S1967QfsX84) (19) , (p.R521H) (20) , (p.R621Q) (21) , (p.I771T) (22) , (p.R815Q) (23) , (p.I1023V) (24) (p.A1383T) (25) and (p.E1974H) (26) (Fig. 1B) . However, the underlying basis leading to phenotypically distinct syndromes from several genetic mutations of MED12 remains unclear.
MED12 gene is located at Xq13.1 and together with MED13, CDK8 and Cyclin C (CCNC) forms the Kinase module, that variably associates with the core Mediator (27) . MED12 is required for the stable incorporation of CDK8/CCNC into Mediator and appears to initiate the CDK8 kinase activity (28) which can regulate transcription (29) . For example, CDK8 phosphorylation of Pol II leads to the disruption of Mediator-Pol II interactions thus resulting in transcriptional inhibition (30) . Similarly, CDK8 phosphorylates Cyclin H, a subunit of the general transcription/ DNA repair factor TFIIH, and thus represses both the ability of TFIIH to activate transcription and its CTD kinase activity (31) . MED12 has also been linked with the Notch, Wnt and Sonic hedgehog signalling pathways and control key aspects of brain development and function, from initial patterning to neuronal plasticity (32) (33) (34) (35) (36) (37) .
Here, we first describe a male patient with characteristics including intellectual and developmental delay (38) . He was found to carry a maternally inherited missense mutation in MED12 (MED12/p.R1295H). In an attempt to deepen our knowledge about the role of Mediator in the regulation of gene expression, we have deeply investigated the effect of this mutation on the transcriptional activation of key genes. We discovered that this MED12 mutation specifically modulates the expression of activated immediate early genes (IEGs) such as JUN (MIM: 165160) by disturbing the formation of the transcription complexes.
Consequently, late response genes (LRGs) that are regulated by the AP1 complex (FOS/JUN dimer) are also disrupted. We then enlarged our study to seven different mutations and come across distinct deregulation of JUN/FOS(MIM:164810)/ EGR1(MIM:164810) expression, possibly explaining the large clinical spectrum covered by MED12-related patients. This might challenge clinicians to rethink the traditional syndromes boundaries and to reconsider patients' diagnostic through genetic criterion.
Result

MED12/p.R1295H mutation disturb IEGs expression
Mediator is known to mediate the response of IEGs, involved in diverse processes such as brain development and neuronal plasticity (10, 39) . To evaluate the global impact of MED12 on IEGs expression, we used CRISPR/Cas9 system to Knock-Down MED12 in human LAN-1 neuroblastoma cell line (MED12-KD). We first observed that silencing MED12 does not impact the level of other Mediator subunits (Fig. 1C) . We thus evaluated the expression of three IEGs: JUN, FOS and EGR1 which code for DNA binding factors, 30 min after serum addition to wild type (WT) and MED12-KD cells. Quantitative RT-PCR on total mRNA extract clearly showed that JUN, FOS and EGR1 expression is down regulated in MED12-KD cells (Fig. 1D) as confirmed by the decrease of their protein synthesis (Supplementary Material, Fig.  S1 ).
We next focused on a MED12 patient from whom skin fibroblasts had been obtained (Table 1 ; Supplementary Material, Fig.  S2A and B; see 'Materials and Methods' section ). The R1295H patient and his heterozygous mother carried a G-to-A missense substitution at nucleotide position c.3884 resulting in an arginine to histidine modification (p.R1295H) referred as R1295Hson and R1295Hmother, respectively (Fig. 1E ). This patient is currently monitored for intellectual disability and delayed motor skills. He has a Marfan habitus (MIM: 154700) and was suspected to have X-linked Lujan-Fryns syndrome. His mother had the same skeletal and morphologic features as well as a mild intellectual disability (38) . Sanger sequencing of the MED12 transcript revealed that $80% of cultivated mother fibroblasts express the mutant allele, due to skewed X-inactivation. RTqPCR and Western blot analysis on both patient and mother fibroblasts shows that the mutation does not significantly affect mRNA expression of MED12 and MED23 subunits of Mediator as well as the corresponding protein level (Supplementary Material, Fig. S3 ). However, we repeatedly observed that CDK8 subunit of the Kinase module was slightly less expressed in R1295H fibroblasts (Supplementary Material, Fig. S3 ).
In response to serum mitogens, JUN activation was defective in both R1295Hson and R1295Hmother fibroblasts while FOS and EGR1 were similarly expressed when compared with WT cells (Fig. 1F) . In order to gain confidence in the consequence of MED12/p.R1295H mutation in IEGs serum induction response, we performed clonal selection (cs) from the R1295H mother's fibroblasts and obtained cells expressing only one allele due to X-inactivation (see 'Materials and Methods' section). In csR1295H clone selected cells, we similarly observed that JUN was down regulated compared with clone csWT while FOS and EGR1 (according to P-value) were not modified (Fig. 1G ). This result emphasized what was first observed with patient fibroblasts (Fig. 1F) . Therefore we decided to use these cells as references in the following experiments.
Deregulation in the transcription complex formation at the JUN promoter
To further understand how a single point mutation disrupt the expression of a given gene, we set up Chromatin Immunoprecipitation (ChIP) experiments. We observed that the absence of JUN induction correlate with the defective recruitment of MED12 and CDK8 part of the kinase module as well as Pol II and TFIIB, a general transcription factor (Fig. 2A1-A4 ). JUN is regulated by several responsive elements, including one that is targeted by transcription factor 4 (TCF4), involved in neurological development and mutated in Pitt-Hopkins syndrome (40-42) Even though TCF4 was normally recruited at its distal responsive element (data no shown), its interaction with the basal transcription machinery via Mediator is strongly disturbed in R1295Hson cells when compared with WT cells (Fig. 2A5) . Corresponding with the normal levels of FOS and EGR1 expression, we observed a normal recruitment of MED12, CDK8, Pol II, TFIIB, as well as the phosphorylated form of ELK1 (ELK1-P) at their promoters (Figs. 2B1-B5 and 2C1-C5). FOS and EGR1 expression are regulated by the cooperative binding of ELK1, ELK3 or ELK4 to serum response elements (SREs) in WT cells. These factors which belong to the ETS family have roles in various contexts, including long-term memory formation, drug addiction, Alzheimer's disease, Down syndrome and depression (43) (44) (45) .
Gene activation is accompanied by important chromatin remodelling events. Euchromatin, which enables transcription to occur, is mainly characterized by acetylation of H3K9 histone Expression of JUN, FOS and EGR1 were monitored in both csWT and in csR1295H. (*corresponds to P < 0.05; **corresponds to P < 0.01).
(H3K9ac) while heterochromatin which inhibits RNA synthesis, is characterized by a different set of chromatin markers such as dimethylation of H3K9 (H3K9me2) (46, 47 and A7). Altogether the above data clearly showed that the MED12/ p.R1295H causal mutation drastically affects the expression of JUN by disturbing the formation of an active transactivation complex on its promoter.
MED12/p.R1295H mutation deregulates a large set of genes
We next examined the biological consequences of IEGs deregulation on the expression of LRGs. We have sequenced total RNA extract 3h after serum induction, from both R1295Hson and WT cell lines. We determine log2-fold change between non-treated and treated cells in both control and R1295H patient (Fig. 3A) . With a minimum ratio of 2 between inductions, we observed a severe deregulation of a large set of gene (Fig. 3A) . Globally, ChIP-seq experiments on both Pol II and MED12 further showed a significant reduction of the recruitment of these two essential proteins around the TSSs all over the genome, 3 h after serum induction (Fig. 3B) . Interestingly, we noticed the identical 3C ). On such genes, we detected a much lower enrichment of elongating Pol II along the genes body in R1295H patient cells compared with WT cells (Fig. 3D) . Interestingly, genome ontology reveals that these genes are implicated in several neurological processes (Fig. 3E) . Notably, numerous genes are implicated in neural differentiation and proliferation, two pathways known to be associated with macrocephaly.
LRGs expression
AP1 is a transcription factor composed of proteins belonging to JUN and FOS families that regulates lately expressed genes through its binding to specific AP1 sites, as show on diagrams Figure 4 (below expression panel of each genes) (48) . We then tested the expression of three AP1 responsive genes 3 h after serum induction. The matrix metalloproteinase-3 (MMP3, also known as Stromelysin-1), implicated in spatial learning, neural and synaptic plasticity (49, 50) , was down regulated in the R1295Hson cells compared with WT cells ( Expression of Cyclin D1 (CCND1, MIM:168461) that connects the AP1 complex with G1 phase progression (51), was not modified (Fig. 4B1 ). Pol II, Mediator subunits as well as JUN and FOS were similarly present at the CCND1 promoter ( Fig. 4B2 and B6 ), on which the methylated status of H3K9 histones was not altered in R1295Hson cells when compared with WT ( Fig. 4B7) .
We also investigated the expression of the RE1 silencing transcription factor (REST, MIM: 600571), also known as neuron restrictive silencer factor that suppresses the non-specific expression of neuronal genes in terminally differentiated non-neuronal cells (52) (53) (54) . REST contains two alternative TSSs producing two isoforms (NM_005612.4/NM_001193508.1); one putative AP1-binding site was located near the second TSS (REST2). REST1 expression that lacks AP1-binding site was not affected by the MED12/p.R1295H mutation (Fig. 4C1) . At the REST1 promoter in which JUN/FOS was absent ( Fig. 4C5 and C6 ), we repeatedly detected low and similar levels of Pol II, MED12 and MED6 in both R1295Hson and WT fibroblasts (Fig. 4C2, C5 and C6). On the contrary, REST2 isoform was up regulated in the patient cell line when compared with WT cells (Fig. 4D1 ). We detected a higher level of recruitment of Pol II and MED12 in patient cells ( Fig. 4D2 and D5) . Surprisingly, we also observed a disruption of the JUN/FOS ratio recruited at the REST2 promoter when compared with what happens in WT cells ( Fig. 3D3 and  D4 ). The recruitment of the core Mediator (as visualized by MED6) was not affected by the MED12/p.R1295H mutation (Fig. 4D6 ). It was difficult to decipher the relative level of H3K9me2 enrichment around both REST1 and REST2 promoters due to their close proximity ( Fig. 4C7 and D7 ).
Finally, we were curious to evaluate the expression of Synapsin I (SYN1, MIM:313440), a REST-dependent neuronal gene involved in the regulation of neurotransmitter release as well as axonogenesis and synaptogenesis (55) . One mutation in this gene was found to segregate with X-linked disorders and to be associated with aggressive behaviour, macrocephaly and learning problem (56) . SYN1 expression was significantly down regulated in R1295Hson cells (Fig. 4E1 ). Pol II presence at SYN1 promoter, was quite similar in both cells (Fig. 4E2 ) when REST is slightly more present in patient cells (Fig. 4E3 ). However, it seems that the lower expression of SYN1 could also be explained by the absence of MED12 and EGR1 recruitment ( Fig. 4E4  and E5 ). We noted that the repressive H3K9me2 marks were not observed around SYN1 promoter in both cells (Fig. 4E7 ). All together our data pointed out the cascade effect that occurs on the LRGs when the JUN expression was deregulated.
Specificity of MED12 mutations on IEGs expression
To provide explanations to the large and diverse clinical spectrum covered by MED12-related patients, we enlarge the study to seven different mutations. In addition to the already identified MED12 mutations associated with Opitz-Kaveggia syndrome (p.R961W) (14) , Lujan syndrome (p.N1007S) (16) and Ohdo syndrome (p.R1148H and p.S1165P) (18), we ascertain the role of three additional mutations p.R206Q, p.N898D and p.R1295H (Fig.  1B) . All these residues are conserved across all MED12 orthologs, from Xenopus to human (Supplementary Material, Fig. S4 ). These three patients were not diagnosed a priori as having a MED12-related syndrome although they share some clinical features ( Table 1 ). The patient with the p.R206Q substitution only shares the major symptoms such as intellectual disability, tall stature and macrocephaly. The patient with the p.N898D mutation (Supplementary Material, Fig. S2C ) exhibited more clinical features such as his facial trait and 'gestalt' quite close to those of FG syndrome (57), as observed for the FG patient bearing p.G958E mutation (15) . His mother presently dead was bearing the hemizygous mutation and presented some minor intellectual disability and some facial morphological features. Another patient with the p.R1295H mutation was enrolled with his brother in a cohort of families with XLID and was sharing some features associated with Lujan syndrome, despite it was difficult to arrive at a single diagnosis for both.
To further conduct our investigations, we used Epstein-Barr Virus (EBV)-immortalized lymphoblastoid cells more easily to collect. RT-qPCR showed that all the five mutations did not significantly affect mRNA expression levels of Mediator 
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ChIP experiments next showed that the recruitment of Pol II and MED12 at their respective promoter parallels the expression level of JUN, FOS and EGR1 (Fig. 5C2 and C3 , D2 and D3 and E2 and E3). The recruitment of TCF4, at the responsive element of JUN promoter is impaired when Pol II and MED12 binding is defective ( Fig. 5C4 and C5, lanes 2, 4 and 5) . In R961W, N1007S and R1295H cells, the up-regulation of FOS parallel the reduced binding of ELK1-P which is compensated by an increase binding of its paralog ELK3 on the SRE element (Fig. 5D4-D5, lanes 4-6) . We also observed a higher binding of ELK1-P and a lower binding of ELK3 at the FOS promoter in R206Q cells ( Fig. 5D4 and D5 , lane 2). In N898D cells, neither ELK1-P nor ELK3 were detected at SRE (Fig. 5D4 and D5, lane 3) . However, in these two cell lines, FOS seems to be normally expressed (Fig. 5D1, lanes 2 and 3) . In both R206Q and N898D cells, where EGR1 is down regulated, neither ELK1-P nor ELK3 are recruited at SRE (Fig. 5E4 and E5 , lanes 2 and 3), while in the R961W, N1007S and R1295H cells as well as in WT cells, we observed ELK1-P recruitment (lanes 1 and 4-6).
Knowing that each gene can be under the control of different stimuli, we also investigated the behaviour of JUN and FOS when cells were submitted to another cellular stress such as UV irradiation. Contrary to what was observed under serum mitogen stress, JUN is not down regulated but even seems to be up regulated in R206Q cells (Supplementary Material, Fig. S8A , lane 2). In UV treated R961W and R1295H cells, FOS seemed to be similarly overexpressed compared with what occurred in serum induced cells. However, we observed a much lower stimulation in N1007S cells and a significant increase in R206Q cells (Supplementary Material, Fig. S8B lanes 4, 6 and 5, 2 , respectively). Our data show that MED12 patients might be sensitive to other cellular stress. We also investigated the effect of MED12 mutations on the expression of the RARb (MIM: 180220) gene induced by all trans retinoic acid (t-RA), that mediates cellular signalling during embryonic morphogenesis, cell growth and differentiation (58) . Every t-RA treated lymphoblastoid cell lines, except N1007S cells, accumulated RARb mRNA (Supplementary Material, Fig. S8C, lane 5) . This demonstrate that JUN and FOS are sensitive to any kind of stress in general.
All together, the above data significantly showed that each MED12 mutations might lead to a specific pattern of IEGs expression, resulting from impairment in the formation of the transactivation complex. This will undoubtedly influence the LRGs in a different manner.
Discussion
In an attempt to dissect the complicated molecular mechanisms underlying the control of gene expression, we decided to deeper our knowledge on the large multi-subunit Mediator complex. In human, the central role of Mediator was highlighted by the discovery of mutations in some of its subunits leading to severe genetic disorders (8) (9) (10) 15, 16, 18) . Among MED subunits, MED12 is the part of the Kinase module that plays a crucial role in gene expression regulation (4,5,31). Our work first revealed that MED12 knock down in human neuroblastoma cells significantly reduced the expression of JUN, FOS and EGR1, three genes involved in brain development and plasticity (Fig. 1D ) (12, 39, 59, 60) .
We focused on several missense MED12 mutations responsible for broad and diverse clinical features. Although patients share some similar characteristics such as intellectual disabilities, several were not diagnosed a priori as having a MED12 associated syndrome, such as Lujan, Opitz-Kaveggia or Ohdo syndromes ( Table 1) .
As Mediator serves as a link between gene specific-binding factors and the basal transcription machinery, we investigated the activity of several genes in cells carrying MED12 mutations. We then observed that the MED12 mutations led to the abnormal and specific deregulation of IEGs expression. For example, MED12/p.R206Q,/p.R961W and/p.N1007S disrupt JUN expression (Fig. 5C1) . In such cases, TCF4 was not properly recruited to its binding element (Fig. 5C5) and was then unable to contact the basal Pol II transcription machinery on proximal promoter (Fig. 5C4) . Similarly, MED12/p.R961W,/pN1007S and/p.R1295H mutations up regulated FOS expression (Fig. 5D1) , through a change in the correct configuration of the transcription machinery at the IEGs (e.g. ELK3 recruitment instead of ELK1, Fig. 5D2-D5) . A third example was provided by the MED12/p.R206Q and/p.N898D that down regulated EGR1 expression due to the absence of an ELK proteins in the transactivation complex ( Fig. 5E4 and E5) .
We also question about the cause that prevent normal Mediator function. Although MED12 mutations were shown not to disrupt the formation of the Mediator complex in solution (Fig. 5A) , it is likely that they modify in some way the intrinsic stability of the complex, leading to incomplete binding of the kinase module within the transcription complex. In vitro investigations predicted a role for the Kinase module of MED toward several substrates such as TFIIH, Pol II, as well as CDK8 itself in the context of activated gene expression (28) . Moreover, it was also shown that the Kinase complex incorporation within MED was essential for CDK8 substrate specificity. When MED12 is required for stable incorporation of CDK8/CCNC into MED, it is also required to activate the CDK8 kinase. Here we found that the kinase module (according to ChIP experiments on MED12 and CDK8) did not properly target the JUN promoter ( Fig. 2A1  and A2 ). Consequently, inaccurate expression of IEGs coding for DNA-binding factors, will further modify LRGs expression through a consecutive sequence of events. Indeed in the R1295Hson cells, the deregulation of MMP3 and REST2 expression might be explained by a modification in the JUN/FOS recruitment at their respective promoters (Fig. 4A3-A4 ). It is likely that MED12/p.R1295H associated defect in bridging DNA binding factor to Pol II machinery could also be responsible at least partially, for such deregulation. We indeed observed some changes in the Kinase(MED12)/Core-Mediator(MED6) ratio at the MMP3 and/or SYN1 promoter compared with WT cells (Fig. 4A5, A6 and E5, E6). It is clear that MED12 mutations lead to a modification of the correct configuration of the transcription machinery at the IEGs and the LRGs promoter, which resulted in the modification of the transcriptional programme in the patient cells. The specificity of individual mutation also depends on the cellular context as shown for the FOS expression in MED12/p.R1295H fibroblasts or for the expression of RARb in N898D fibroblasts versus lymphoblastoids cells (Supplementary Material, Fig. S9) .
Our study has shown that the MED12 mutations led to the abnormal expression of IEGs and resulted in changes into LRGs expression. Ultimately, these results suggest that the different phenotypes caused by the different mutations are essentially the result of the above to varying degrees. The deregulation of JUN, regarded as a marker of neural activity and its involvement in partnership with FOS, partially explained the neurological phenotypes of the patients as summarized Table 1 . Although the gene regulation abnormalities do not precisely explain the clinical phenotypes, we observed significant down-regulation of genes containing AP1-binding site targeted by JUN/FOS complex. Gene Ontology enrichment then shows that most of these genes are involved in development and neurological processes. Further investigations on the expression patterns of certain genes including MMP3, REST2 and SYN1 in neural cells will help to decipher the specific consequences of MED12 mutation in neurological context. Future studies should help to elucidate the genotype/phenotype relationship of the patients with MED12 mutations.
We noticed some heterozygous mother with missense mutation to share part of the symptoms (e.g. mild intellectual disability). MED12 is located on chromosome X and one of its two alleles is inactivated in females. We have observed that most of cultivated heterozygous fibroblasts (about 80%) from the mother of the MED12/p.R1295H patient express the mutated allele. This skewed XCI phenomenon might explain why the MED12/ p.R1295H and/p.N898D mothers exhibit similar but milder clinical features than their sons. Actually, the partial maternal symptoms could be explained by a stochastic effect occurring at two different times: at the early embryonic stage of the X-inactivation process and lately during the embryonic organ specification due to a random redistribution of founder cells. This random process could be systematically skewed in some cases due to preferential inactivation of the wild allele. We could not discard this hypothesis since MED12 was implicated in the activation of non-coding RNA. In this way, mutated MED12 might have a possibility to disturb the balance of XIST and/or TSIX non-coding RNAs transcription which control the X-inactivation process (61) . In fact, a defect of XIST in tiny ring X chromosome patients is already know to result in developmental and cognitive disorders (62) .
A number of human diseases with IEG expression affecting brain development and plasticity are caused by mutations in genes encoding for MED subunits or proteins interacting with MED, such as nucleotide excision repair factors or chromatin remodellers. Mutations of MED13L, MED17, MED23 or MED25 are responsible for infantile cerebral and cerebellar atrophy, nonsyndromic mental retardation and Charcot-Marie Tooth disease (8) (9) (10) (11) . Mutations in TCF4, which interact with the Mediator, result in the Pitt-Hopkins syndrome (42) . Examples are also provided by xeroderma pigmentosum (XP, MIM:278730) patients that have progressive neurological degeneration as well as both trichothiodystrophy (MIM:610675) and Cockayne syndrome (MIM:610651) patients that are mentally retarded (63, 64) . It is likely that more and more mutations in MED and its transcription partners will be detected in patients with cognitive deficiencies as sequencing becomes more commonly used. Therefore, one could speculate that these patients should be classified on a genomic basis rather than distinct syndromes.
Material and Methods
Cell culture
Human lymphoblastoïdes cells were generated by EBV transformation of the peripheral blood lymphocytes isolated from patients. Human primary fibroblasts were isolated from patient's skin. Informed consent was obtained from all subjects before sample collection.
The cs of R1295Hmother fibroblast was done by successive dilution and confirm by Sanger sequencing of total mRNA. CRISPR/Cas9 system was used to Knock-Down MED12 in neuroblastoma LAN-1 cell line. A targeting vector was constructed on the bases of the pPGKNEO-DTA (addgene no. 13443). 5 0 arm spanning intron 2/exon 3 (1 kb, HindIII/AgeI) and 3 0 arm spanning exon 5/intron 5 (960 bp, NheI/XhoI) were PCR amplified from genomic DNA of LAN-1 neuroblastoma cells and sequentially cloned into the first pPGKNEO-DTA vector using respected enzymes. Furthermore a GFP was amplified from pEGFPC1 vector and inserted via restriction digest (AgeI/NcoI) so that exon 3 and GFP will be translated in frame. A guiding RNA targeting exon 3/intron 3 junction was designed and cloned into p459 vector (addgene no. 48139). All constructs were verified by sequencing. All together the targeting vector and CRISPR/Cas9 system targeting the end of exon 3 were transfected into LAN-1 neuroblastoma cells using Amaxa nucleofection protocol. Cells were briefly selected with puromycin for first 2 days and with neomycin for next two weeks. Clones were first pre-screened for GFP expression and further verified by genomic PCR for absence of exon 4 and Med12-specific integration of targeting vector.
Med12 3 arm fw CCAAGCTAGCTAACTCCTAACACCAGGTGTACT GC Med12 3 arm rv CCCTCGAGCAAGCTTACACAGCATGCCCTACTC TCTACC Med12 5 arm fw TCAGATCTCGAGCTCAAGCTTGGTCAGCCTAGG AGGAGGCACTG Med12 5 arm rvATGGTGGCGACCGGTGGGGCTAGTTGCGTGAGT GGCTTGG px4_3ex_Med12_fwcaccgAAAAGGTAAGGTACTGTTTC px4_3ex_Med12_rvaaacGAAACAGTACCTTACCTTTTc
All the cells were cultured in appropriate medium and maintained at 37 C in 5% CO 2 environment.
For serum inductions, cells were incubated in red phenolfree medium without serum for 24 h before treatment by addition of serum (15% final concentration) directly into the medium. For retinoic acid inductions, cells were incubated in red phenol-free medium containing charcoal treated Fetal Calf Serum and antibiotics before treatment with 10 mM tRA (Biomol) into the same medium. For UV inductions, cells were first PBS wash then 4 millions of lymphoblastoid cells in 2 ml of PBS were spreading on a 10-cm dish. Cells were exposed to UV irradiation (20 J/m 2 ) and medium added back.
RNA extraction, reverse transcription and real-time qPCR
Total RNA was extracted with RNeasy mini kit (QIAgen) and reverse transcribed with poly-dT primer using Superscript II reverse transcriptase (Invitrogen). Real-time quantitative PCR was carried out on the Lightcycler 480 using SYBR Green I Master (Roche). The primer sequences are available in Supplementary Material. mRNA levels represent the ratio between values obtained from treated cells compared with untreated cells normalized against the housekeeping Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA.
Co-immunoprecipitation assays
Cells were harvest in lysis buffer (50mM Tris HCl pH7.5, 150 mM NaCl, 1mM EDTA, 1% Triton) with protease inhibitor cocktail (PIC). 200 mg of whole cell extract were incubated with protein G magnetic bead (dynabead, invitrogen) and 2 mg of antibodies. After washes at 300 mM salt, beads were boiled in Laemmli buffer and proteins were separated by SDS-PAGE, transferred to nitrocellulose membrane and probed with antibodies.
Chromatin immunoprecipitation
After treatment, cells were crosslinked at room temperature for 15 min with 1% formaldehyde. Cells were lysed in shearing buffer (50 mM Tris-HCl pH8, 10 mM EDTA, 1% SDS) with PIC at 4 C for 15 min. Nucleus were pelleted and resuspended in sonication buffer (50 mM Hepes pH7.6, 140 mM NaCl, 1 mM EDTA, 1% Triton X100, 0.1% Na-deoxycholate, 0.1% SDS) with PIC. Chromatin was shared using 800R sonicator (Qsonica). Samples were immunoprecipitated with antibodies at 4 C overnight followed by addition of a pre-blocked mix of protein G-and A-Sepharose beads (GE Healthcare Life Sciences) for 3 h at 4 C. Bound complexes were sequentially washed with sonication buffer, high salt buffer (sonication buffer at 300 mM NaCl) and TE buffer (10 mM Tris, 1mM EDTA). Protein-DNA complexes were eluted, and DNA fragments were purified using QIAquick PCR purification kit (QIAGEN). qPCR was performed as described earlier using sets of primers available in Supplementary Material. All the results are presented as 'fold recruitment' and represent the ratio of input percentage between treated and non-treated cells.
Plasmids
MED12 expression plasmid was obtained using the Gateway Invitrogen cloning method. WT MED12 was amplified from a cDNA bank of control lymphoblastoid cells and cloned into pDONR207 (Invitrogen) using standard BP reaction. The cloned sequence was then transferred by LR reaction into pSG 5 puro B10 tag vector (N-terminal fusion of the epitope B of the human estrogen receptor). This vector was constructed by inserting the attL1 and attL2 Gateway linkers (Invitrogen) into the pSG 5 vector backbone. PCR-based mutagenesis was performed using Phusion High-Fidelity DNA Polymerase (New England BioLabs, inc.) with primer bearing a point mutation for the amino changes R206Q, N898D, R961W, N1007S and R1295H. MED12 expression plasmid was transfected using Jet PEI (Polyplus) in HeLa cells, 48 h before the experiments.
Antibodies
For Western blot, the following antibodies were used: MED6 (santacruz, sc-9434), MED12 (Bé thyl, A300-774A), MED22 (santacruz, sc-393738), MED23 (BD Pharmingen, 550429), CCNC (santacruz, sc-1061) and b-tubulin (TUBB) (millipore, MAB3408).
For immunoprecipitation, the following antibodies were used: monoclonal antibodies against B10 (IGBMC), RNA Pol II (IGBMC, 1BP 7C2), ELK3 (IGBMC, 5NE 2F3A2) and polyclonal antibodies against BSA (santacruz, sc50528), MED6 (santacruz, sc-9434), MED12 (Bé thyl, A300-774A), TFIIB (santacruz, sc-225), TCF4 (santacruz, sc13027), ELK1-P (santacruz, sc8406), JUN (santacruz, sc-45 or sc 822), FOS (santacruz, sc-7202), REST (Bé thyl, A300-539A) and H3K9ac (cell signalling, no. 9671 or no. 9649) and H3K9me 2 (cell signalling, no. 9753).
Mutation screening of the MED12 gene
Genomic DNA was prepared from lymphocytes according to standard protocols. Table 1 . Patient K9467 (with mutation MED12/p.N898D): A single male is affected in K9467. The mother had a prior spontaneous abortion. The birth weight was 3.4 kg and the length was 50 cm. Imperforate anus and cryptochidism were present and corrected surgically. Development was globally delayed with independent walking and first clear words achieved at age three years.
Special education was required. Intellectual performance was mildly impaired with a full scale IQ of 58. At age 6 years, he had a height of 113.5 cm (35th centile) and occipital frontal circumference (OFC) of 55.3 cm (>97th centile). He has a tall and narrow forehead, downslanting palpebral fissures, small posteriorly rotated ears (4.5 cm length), maxillary dental crowding and prognathism. The thumbs were flat with angulation of the distal phalanges and the great toes were broad. Neurological examination was normal. There was a tendency to frustration and psychological lability, intolerance and a short attention span. At age of nineteen years, he has a height of 176 cm, weight of 61 kg and head circumference of 61 cm (>99th centile). Gross motor function is normal, fine motor function is slightly impaired. IQ has not been reevaluated but clinical appreciation is consistent with 6-years old IQ. Behavioural problems are prominent with marked frustration intolerance. Constipation and easy vomiting still required permanent medical management (Supplementary Material, Fig.  S2C and D) .
His mother presents with similar but milder dysmorphic features. She suffered from obstinate constipation. She had normal intelligence but some choleric behavioural problems. Unfortunately, she suddenly died of intracranial aneurysm rupture at the age of 47 years.
Patients K9338 (with mutation MED12/p.R1295H): K9338 has two brothers with intellectual disability born to consanguineous parents. They presented with somewhat different phenotypes. One had congenital anal stenosis that was dilated, undescended testes, an umbilical hernia and bilateral inguinal hernias He was very excitable as a child and this transitioned into tantrums and restlessness as a teen. IQ testing, age 11 years, gave a score of 58. The second male was hypotonic, slow to feed and developed slowly, and did not walk until after age 2 years. He also had undescended testes, finger contractures at the PIP joints, hammer toes and a gap between toes 1 and 2. Additional clinical findings are listed in Table 1 . Sequencing of 718 genes on the X chromosome identified a c.3884G > A, p.R1295K mutation in one of the males which was subsequently found in his brother.
Patients A.J. (with mutation MED12/p.R1295H from FRANCE). A.J. was the second child of unrelated parents. His two brothers were in good health. He was born at term (40 WG) after an uneventful pregnancy. Birth weight was 3.1 kg. The neonatal course was uncomplicated but he had delayed developmental milestones. At 22 months, it was noted a global hypotony and some morphologic particularities. Ophthalmological and heart examinations, as well as abdominal ultrasound, echocardiography and CT scan findings were unremarkable. He walked at age of 24 months. Speech was slightly delayed. At age 4 years, he had an orchiopexy because his left testis was on the inguinal canal. During childhood, he suffered from repetitive strain injury. From the age of 7, he had school difficulties and was enrolled in a school mainstreaming class. He had a nasal speech and a long and thin habitus. At age 20 years, his height was 188 cm (þ2DS), weight was 68.5 (þ1.5DS) and OFC was 57 cm (þ2DS). Arm span was 184 cm. Thoraco abdominal examination showed a mild scoliosis, pectus excavatum, two surnumemary nipples and a hypotonic abdominal wall. The facial features included a long and hypotonic face, moderate hypertelorism, bilateral ptosis with epicanthus, down slanting palpebral fissures, everted lower eyelids, arched, large and sparse eyebrows, medially flaring, malar hypoplasia, a long nose with high and narrow nasal bridge, thin upper lip, teeth malposition with absence of the upper lateral incisors and first molars. Ears were small and low-set with thick helices. Joint laxity, long digits, without a positive thumb sign and flat feet were present. Audiometry evaluation, EEG, metabolic screen in blood and urine, endocrinologic and cytogenetic screen (karyotype, comparative genomic hybridization (CGH) array) were all normal. Ophthalmologic evaluation showed a left divergent strabismus (Supplementary Material, Fig. S2A and B). His mother had the same skeletal and morphologic features with a long and hypotonic face, high arched eyebrows, bilateral ptosis, a long filtrum, teeth malposition. She had moderate learning difficulties but none intellectual disability. Her height was 173 cm OFC was 56.5 cm (þ1.5DS). Echocardiography showed a mitral valve prolapse requiring simple monitoring. She underwent surgery for left divergent strabismus and suffered from repeated ankle sprains and early arthrosis of the hip. As her son, she had a nasal speech.
Patients' consent. R1295H fibroblasts were obtained at CHU Clermont-Ferrand and provided by C.F. Informed and written consent was obtained from the patient and his mother. N898D cell lines were obtained at CHU Grenobles and provided by C.C. and P.S.J. Informed and written consent was obtained from the patient and his father. S1165P and R1148H cell lines were obtained at Donders Institute for Brain and provided by AdB. Informed consent was obtained from all families as published in Vulto-van Silfhout et al. (18) . R206Q, R961W, N1007S and R1295H lymphoblastic cell lines were obtained through the X-linked mental retardation (XLMR) study at the Greenwood Genetic Centre and provided by CES. Informed consent was obtained from all families as published for R961W (14) , N1007S (16) and presented at the 2014 annual meeting of the American Society of Human Genetics for R206Q and R1295H. XLMR research at the Greenwood Genetic Centre has been approved by the Institutional Review Board at Self Regional Hospital in Greenwood, SC.
Supplementary Material
Supplementary Material is available at HMG online.
